Corcept Therapeutics Incorporated
CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 dā¦ read more
Healthcare
Biotechnology
22 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$51.16
Price-0.08%
-$0.04
1Y
Price
Market Cap
$5.492b
Mid
Price/Earnings 3y Avg5y Avg
146.2x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-30.1%
EBITDA Margin-18.9%
Net Profit Margin-10.3%
Free Cash Flow Margin-30.1%
EBITDA Margin-18.9%
Net Profit Margin-10.3%
Free Cash Flow MarginRevenue
$769.096m
+1.0%
1y CAGR+17.9%
3y CAGR+18.5%
5y CAGREarnings
$47.903m
-51.9%
1y CAGR-16.3%
3y CAGR-11.1%
5y CAGREPS
$0.35
-57.3%
1y CAGR-19.9%
3y CAGR-12.9%
5y CAGRBook Value
$637.987m
$814.881m
Assets$176.894m
Liabilities$9.637m
DebtDebt to Assets
1.2%
-1.4x
Debt to EBITDAFree Cash Flow
$119.788m
-15.5%
1y CAGR+3.8%
3y CAGR+4.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company